Observational Study on Personality and CML Treatment Adherence
This observational study is looking at how a person's personality might affect how well they stick to their medication schedule for chronic myeloid leukemia (CML). Researchers want to see if there's a connection between personality and taking tyrosine kinase inhibitor (TKI) medicines like imatinib, dasatinib, bosutinib, or nilotinib as prescribed. You could join if you are 18 or older, have CML in the chronic phase, and are currently taking one of these TKI medications. The study will assess how well you take your medication, your personality, and your quality of life over a period of up to one year. This study is currently unclear on its recruitment status.
- Study design
- This is an observational study planning to include 75 participants. It aims to understand the relationship between personality and medication adherence in people with chronic myeloid leukemia.
- What's involved
- You would participate in an in-person interview with a study coordinator to complete questionnaires about your medication adherence, personality, quality of life, and symptoms.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your medication adherence, personality, and quality of life will be assessed for up to one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Mahtab Jafari, Pharm.D · PRINCIPAL_INVESTIGATOR · Chao Family Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Assessment of adherence to TKI medicationUp to 1 year
This will be measured by Morisky Medication Adherence Scale (MMAS), an 8-item tool related to adherence behavior include forgetfulness, stopping medication because of worsening of symptoms or improvement in health condition, and inconvenience of continuing medication. Each item is scored 0 or 1 depending on whether the patient answers yes or no, with a minimum score of 0 and maximum score of 8
- Personality assessmentUp to 1 year
Patient personality will be assessed using the Mini International Personality Item Pool (mini-IPIP) questionnaire. In the mini-IPIP, each of the five factors (openness, conscientiousness, extraversion, agreeableness and neuroticism) is assessed with four items, making a total of 20 items. Each item is scored on a scale of 1 through 5, with 1 indicating "very inaccurate" and 5 corresponding to "very accurate"
- Assessment of quality of LifeUp to 1 year
This will be measured by European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30). EORTC QLQ C30 includes 30 items that measure global health status, functioning, and symptoms.
- Assessment of quality of Life and symptom burdenUp to 1 year
This will be measured by European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia -24 scales.(EROTC QLQ-CML 24). The EORTC QLQ CML 24 is a 24-item questionnaire developed exclusively to assess QoL issues in patients with CML